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Abstract: Psychogenic nonepileptic seizures (PNES) can significantly affect an individual’s 
quality of life, the health care system, and even society. The first decade of the new millennium 
has seen renewed interest in this condition, but etiological understanding and evidence-based 
treatment availability remain limited. After the diagnosis of PNES is established, the first thera-
peutic step includes a presentation of the diagnosis that facilitates engagement in   treatment. The 
purpose of this review is to present the current evidence of treatments for PNES published since 
the year 2000 and to discuss further needs for clinical treatment implementation and research. 
This article reviews clinical trials that have evaluated the efficacy of structured, standardized 
psychotherapeutic and psychopharmacological interventions. The primary outcome measure 
in clinical trials for PNES is event frequency, although it is questionable whether this is the 
most accurate indicator of functional recovery. Cognitive behavioral therapy has evidence of 
efficacy, including one pilot randomized, controlled trial where cognitive behavioral therapy 
was compared with standard medical care. The antidepressant sertraline did not show a signifi-
cant difference in event frequency change when compared to placebo in a pilot randomized, 
double-blind, controlled trial, but it did show a significant pre- versus posttreatment decrease 
in the active arm. Other interventions that have shown efficacy in uncontrolled trials include 
augmented psychodynamic interpersonal psychotherapy, group psychodynamic psychotherapy, 
group psychoeducation, and the antidepressant venlafaxine. Larger clinical trials of these 
promising treatments are necessary, while other psychotherapeutic interventions such as hypno-
therapy, mindfulness-based therapies, and eye movement desensitization and reprocessing may 
deserve exploration. Flexible delivery of treatment that considers the heterogeneous backgrounds 
of patients is emphasized as necessary for successful outcomes in clinical practice.
Keywords: conversion disorder, therapeutics, clinical trials, psychotherapeutic interventions, 
psychopharmacological interventions
Introduction
Psychogenic nonepileptic seizures (PNES) are sudden, involuntary seizure-like attacks 
that, unlike epileptic seizures, are not related to electrographic ictal discharges. PNES 
presenting symptoms involve a wide array of nervous system functions, including 
changes in behavior, motor activity, sensation, cognitive, and autonomic functions.
PNES can be initially mistaken as epileptic seizures, and an accurate diagnosis is 
usually delayed by an average of 7 years.1 Diagnosis is usually confirmed via video-
electroencephalography (v-EEG) monitoring in about a quarter of patients referred 
to epilepsy referral centers.2 There are no population-based studies to determine the 
incidence of this disorder, but it has been estimated that 300,000–400,000 people 
may suffer from PNES in the United States alone.3 PNES can greatly affect a patient’s 
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quality of life4,5 and are associated with high medical utiliza-
tion rates and hence also high personal and societal costs.3 
New evidence seems to indicate a higher premature mortality 
rate in PNES subjects than that found in a comparison with 
the Scottish general population, although deaths were not 
seizure related.6
Despite the recognition of this condition and its effect 
on individuals, society, and the health care system, currently 
there are significant limitations in the etiological under-
standing of PNES. Traditionally, PNES have been linked to 
a dysfunction in the processing of psychosocial stress.7 A 
conceptual framework has been proposed that explains PNES 
as involuntary, stimulus-driven behavioral responses facili-
tated by an orienting tendency where cognitive, emotional, 
and sensorimotor systems are not seemingly integrated.8 
This response tendency may take place because of a number 
of vulnerability traits that increase a predisposition toward 
PNES, including dissociative tendencies, alexithymia, cog-
nitive inflexibility, and hypervigilance, to name a few.8 This 
conceptual framework remains hypothetical and highlights 
the lack of a single etiological model that explains this 
phenomenon.9
Once PNES are properly diagnosed, treatment disposi-
tion usually includes a referral to mental health specialists.10 
Traditionally, mental health providers willing to work with 
this population have utilized a variety of personalized psy-
chotherapeutic approaches that address specific psychiatric 
comorbidities and hypothesized mechanisms.11 This may 
be necessary in part because of the heterogeneous psychi-
atric and medical backgrounds usually seen in the PNES 
population.12,13
Guidelines on how to treat this complex population 
do not exist, owing to a lack of large, controlled trials 
evaluating the efficacy of different treatment modalities.14 
In 2007 a Cochrane review looking at existing evidence-
based treatments for PNES showed an alarming lack of 
randomized, controlled clinical trials with solid evidence 
of efficacy.15 According to a search of the PubMed database 
conducted for the present article, there were no clinical trials 
of specific interventions designed for PNES prior to 2000. 
Some follow-up studies undertaken prior to 2000 indicate 
that appropriate referral to mental health treatment had 
positive therapeutic effects. For instance, a follow-up study 
of 28 patients was published in 1999 and showed higher 
rates of event freedom and improvement in patients who 
received psychotherapy; however, the treatment delivered 
was not standardized among participants.16 A retrospective 
analysis of 61 PNES patients demonstrated higher rates of 
event freedom or reduction in those patients who received 
either psychotherapy or feedback and routine neurological 
care than in those who did not receive either. The psycho-
therapy treatment was provided either by a psychotherapist 
from a comprehensive epilepsy center or by community 
psychotherapists; no standardized treatment protocol is 
described to be followed beyond the diagnosis presentation.17 
  Remaining results consisted of isolated case reports for the 
adult population.18,19
The purpose of this review is to present the current 
evidence of treatments for PNES published since the year 
2000 and to discuss further needs for clinical treatment 
implementation and research.
What do we know about other 
PNES-related disorders?
PNES subjects share many underlying psychopathological 
characteristics with other conversion and somatoform disorder 
patients. It remains uncertain what determines the final symp-
tomatic expression of PNES. One study comparing motor con-
version and PNES subjects found a higher incidence of adverse 
childhood experiences and life events in the PNES group,20 
but it is far from clear if this constitutes a causative difference 
between patients who may have loss of consciousness as one 
of their manifestations, such as in PNES, and those with pure 
motor manifestations. Post-traumatic stress disorder (PTSD), 
other anxiety disorders, dissociative disorders, depression, and 
borderline personality disorder are comorbidities frequently 
encountered in PNES patients.21 Given the overlap in psycho-
pathological structure with many of the disorders mentioned 
here, it is relevant to briefly review the current evidence of 
effective treatments for these disorders.
The strongest evidence for other conversion disorders 
comes from two randomized, controlled studies. In the first 
study, 20 patients with motor conversion symptoms received 
weekly sessions of hypnotherapy and the patients’ change in 
conversion symptoms and level of disability were compared 
with a group of 24 subjects in a waiting list. Because the 
semiology of the motor conversion symptoms was mixed, two 
participants had PNES. Tremors, paresis, and gait complaints 
were common. Motor conversion symptoms, rated by the 
Video Rating Scale for Motor Conversion Symptoms, and 
level of disability both showed larger post- versus pretreat-
ment improvement in the active group than in the control 
group. Subjects did not receive other psychotherapy interven-
tions and there were no medication changes during the study, 
although nearly half of the subjects were on psychotropic 
medications at the onset of the trial.22
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In the second randomized, controlled trial, conducted by 
the same research  group, 24 inpatients with motor conversion 
symptoms received eight weekly hypnotherapy sessions and 
were compared with 21 inpatients also with motor conver-
sion symptoms but who received a supportive individual 
intervention instead during the admission. All subjects 
received multidisciplinary group-centered psychotherapy 
interventions and physical therapy. Eight subjects had PNES. 
Both groups showed post- versus pretreatment reductions 
in motor conversion symptoms and level of disability, with 
hypnotherapy providing no additional effect.23
Evidence-based treatment for other conversion disorders 
has also been demonstrated by uncontrolled trials; particu-
larly, physical exercise24 and psychodynamic psychotherapy25 
improve symptom severity in psychogenic movement disor-
ders. Antidepressant medication showed reduction and even 
remission of psychogenic movements if the movements were 
not accompanied by other somatoform disorders such as 
hypochondriasis or somatization disorder.26 Repetitive tran-
scranial magnetic stimulation over the motor cortex showed 
improvement in 62 of 70 patients (89%) with psychogenic 
paralysis, with total recovery observed in 53 (76%) of those 
subjects, although this was a retrospective review instead 
of a prospective trial.27
Two of the studies mentioned earlier for conversion 
disorder22,23 included PNES subjects, but as these patients 
were mixed with other conversion patients and represented 
a minority of subjects within the studies, they were included 
in this section instead of in the PNES-specific review 
section.
Randomized, controlled trials of cognitive behavioral 
therapy (CBT) in somatization and specific-symptom syn-
dromes (such as chronic fatigue syndrome, irritable bowel 
syndrome, chronic pain) have supported the effective-
ness of this intervention.28 Psychodynamic interpersonal 
psychotherapy has also shown efficacy in irritable bowel 
syndrome.29,30 Antidepressants of various classes have also 
demonstrated reduction in medically unexplained symptoms 
including headache, fibromyalgia, functional gastrointestinal 
syndromes such as irritable bowel syndrome, idiopathic pain, 
tinnitus, and chronic fatigue.30,31
A review of the literature examining treatments for dis-
sociative disorders such as dissociative identity disorder, 
depersonalization disorder, and dissociative disorder not 
otherwise specified shows a lack of standardized and well-
designed studies.32 One controlled single case study did show 
improvement in dissociative pathology in a dissociative 
identity disorder patient with cognitive analytic therapy.33 
No other controlled studies have been published for disso-
ciative disorders. It is possible that the need for long-term 
outcome studies may limit the utility of short-term interven-
tions that can be adapted into a randomized, controlled trial 
in this population.32
A review of evidence-based treatments for other PNES-
related primary psychiatric disorders such as PTSD or border-
line personality disorder is beyond the scope of this review. 
Nonetheless, it is noteworthy that there is mounting evidence 
of effective structured psychotherapies, with the most exten-
sively studied psychotherapies being CBT for PTSD and 
other anxiety disorders34 and dialectical behavioral therapy 
for borderline personality disorder,35 although other forms 
of psychotherapy (such as eye movement desensitization 
and reprocessing [EMDR] in PTSD, or mentalization-based 
therapy in borderline personality disorder) and psychophar-
macological interventions have also been investigated.35–39
Awareness of effective therapies in these conditions may 
help customize treatment in PNES subjects with these fre-
quent comorbidities. From a research perspective, therapies 
proven effective in these related pathologies may become 
candidate interventions worth exploring in PNES.
Limitations in PNES clinical trials
A number of obstacles have been identified as contributing 
to the difficulty in conducting large clinical trials in PNES. 
Some of these obstacles are intrinsic to PNES psychopa-
thology, such as the tendency to present in crises but reject 
support when offered, emotional lability, and approach-
avoidance behavioral patterns. Other impairments are logisti-
cal in nature and include driving restrictions, other cognitive 
and physical limitations related to medical and neurological 
illnesses, and a wide range of comorbid neurologic and 
psychiatric comorbidities, including epilepsy, which may 
preclude enrollment based on the study.40
The fields of neurology and psychiatry have played a role 
in the lack of priority given to PNES treatment development. 
Neurologists and emergency physicians tend to dismiss PNES 
patients and may interpret the patients’ events as voluntary 
fabrications. Psychiatrists and psychologists may not treat 
PNES patients for fear of missing epilepsy when patients 
have ongoing events.41 As a result, PNES may be considered 
an “orphan” disorder that neither field wants to own as a 
priority to develop therapeutic approaches for.
The lack of a single etiological model for PNES9,14 limits 
the selection of mechanism-specific interventions and hence 
also limits outcome measures. However, a variety of proposed 
etiological mechanisms (including avoidance,   dissociation, 
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personality structure, interpersonal factors, illness representa-
tion, biological vulnerabilities) may inform treatment choice 
and selection of outcome measures.9,42
Regardless of the etiological model that dictates the 
intervention, useful outcome measures in PNES clinical tri-
als include event frequency or percentage of subjects who 
achieved event freedom, psychopathological measures, social 
and interpersonal functioning measures, medical utiliza-
tion rates, and quality of life.9 Although event freedom is 
usually the primary outcome in PNES clinical trials, it has 
been established that the percentage of functional recovery 
did not differ based on event remission 4.2 years after the 
diagnosis.43 Additionally, the relationship between PNES 
frequency and health-related quality of life is influenced by 
psychopathological severity and other physical symptoms,44 
bringing to light the importance of these other measures that 
are usually considered “secondary.”
Table 1 summarizes the factors enumerated here that 
have implications in the development and conduction of 
PNES clinical trials.
Presentation of the diagnosis: the 
first therapeutic intervention
After the diagnosis is confirmed, presenting the diagnosis 
to the patient and, when appropriate, to his or her family, 
becomes the first therapeutic step toward recovery. Marked 
reduction in health care demand after diagnosis presentation 
has been established by prospective service evaluations.45,46 
For a subset of PNES individuals, awareness that they do 
not suffer from epilepsy and that their events have emotional 
underpinnings is sufficient for the episodes to be under con-
trol, at least for the subsequent 6 months.47 Kanner et al48 
described this subgroup of patients with sustained control of 
their attacks as having a lower degree of psychopathology 
and the ability to recognize stressful events as precipitating 
factors for their attacks.
How the PNES diagnosis is presented has always been con-
sidered a delicate matter, and protocols on how to present the 
diagnosis have been suggested.41,49 Although immediate relief 
after diagnosis presentation has been documented,50,51 mainte-
nance of such immediate improvement has been variable.48,52 
Because engagement in treatment will be crucial for recovery, 
and because PNES subjects are known to have low rates of 
treatment retention,53,54 this “first therapeutic step” is a decisive 
moment that may define the patient’s clinical and functional 
outcome and hence it should be handled carefully.
A standardized protocol for diagnosis presentation was 
used in 50 newly diagnosed PNES subjects in a multicenter 
study. The protocol covered 14 points addressing all domains 
of patients’ illness representations and it was found to be 
acceptable to patients. Fourteen percent at 2 weeks after the 
diagnosis and 20% at 11 weeks after the diagnosis reported 
attack freedom or only occasional events.55
Not uncommonly, health professionals may misinterpret 
the psychogenic origin of these events as a sign of volun-
tary fabrication. Understanding PNES as “faked seizures” 
may generate a negative attitude toward patients, and it can 
behaviorally reinforce reluctance in the patient to accept the 
diagnosis. Although there is no neurobiological evidence 
for PNES at this juncture, it is known from functional neu-
roimaging studies in psychogenic tremor and psychogenic 
paralysis56–58 that brain activation differs between feigned 
and psychogenic symptoms, lending support to the “brain 
basis” of the disorder.
Table 2 summarizes the key points for a successful presen-
tation of the diagnosis based on previous recommendations49,55 
and the author’s own clinical experience at a nonepileptic 
seizure intervention clinic previously held at the University 
of Illinois Medical Center at Chicago.
PNES: renewed interest?
The first decade of the new millennium has seen an increase 
in interest in PNES. A limited search of the PubMed database 
for articles utilizing terms related to PNES in the title or 
abstract showed there were 96 articles published on the topic 
during the 1980s, 243 articles published during the 1990s, 
and 426 articles published during the 2000s. This growing 
interest in the topic has propelled a renewed enthusiasm in 
Table 1 Limitations in the conduction of psychogenic nonepileptic 
seizures (PNES) clinical trials9,14,40–42
Limitations
Obstacles intrinsic to PNES psychopathology
•  Emotional lability
•  Approach-avoidance behavioral patterns
•  Tendency to present in crisis and reject support
•  Lack of motivation (due to depression, reinforcing factors)
Logistical impairments preventing participation in treatment and/or 
enrollment in research
•  Driving restrictions
•    Cognitive limitations (due to intellectual disability, cognitive 
impairment due to neurological illness, cogniform symptoms)
•    Physical limitations (due to pain, physical disabilities from neurological, 
medical, or conversion symptoms)
•    Severity of psychopathology that may limit enrollment in studies 
(suicidality, psychosis, severe depression)
Relative lack of disease “ownership” by medical specialty
Lack of understanding of a single etiological mechanism
Unclear utility of various outcome measures
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identifying treatment interventions for this population. The 
following section will review treatment studies that have been 
published since the year 2000.
Treatment review
Methods
A PubMed literature search was conducted, focusing on treat-
ment studies on PNES from January 2000 through December 
2011. The search included articles with the terms “nonepileptic 
seizures” (as well as “non-epileptic seizures”), “psychogenic 
seizures,” “dissociative seizures,” “conversion seizures,” 
“pseudoseizures,” “psychogenic spells,” and   “psychogenic 
attacks” in the title or abstract. The results of these searches 
were combined with the Medical Subject Headings term 
“therapeutics.” Titles and abstracts were reviewed to identify 
potentially relevant articles, which were then retrieved to 
review the full article. All results were limited to English-
language articles and a study was included if it recruited all 
adult PNES patients only. The intervention being investigated 
had to be described as being delivered as uniformly as possible 
to all subjects. Case reports and case series were excluded. 
The main aspects of these studies are summarized in Table 3.
Results: psychotherapeutic interventions
CBT
CBT is based on the concept that dysfunctional conditioned 
responses and thought processes lead to a misperception 
of reality that presents as psychopathological symptoms.14 
In the case of CBT, PNES are conceptualized as dissocia-
tive responses to arousal when a patient is confronted with 
stimuli or circumstances that the patient tends to avoid, either 
consciously or not.59
CBT is the only psychotherapeutic intervention studied in 
PNES in a pilot randomized, controlled trial60 and it is there-
fore the psychotherapeutic treatment with the highest level of 
efficacy evidence (Class III) in this population. The content 
of Goldstein et al’s59,60 CBT approach emphasizes the fol-
lowing concepts in different stages through twelve outpatient 
sessions: (1) engagement in treatment; (2) reinforcement of 
independence; (3) distraction, relaxation, and refocusing tech-
niques at the earliest signs of an event; (4) graded exposure to 
avoided situations; (5) cognitive restructuring; and (6) relapse 
prevention. In Goldstein et al’s60 randomized, controlled 
trial, both the active and control groups received   “standard 
medical care” (SMC) treatment, comprising up to seven 
neuropsychiatric appointments that focused on psychoeduca-
tion, support measures, and antiepileptic drug   withdrawal. 
Event frequency was not different between analyzed groups 
(CBT + SMC, n = 33; SMC [control], n = 31) at the start 
of treatment (CBT + SMC group median, twelve events per 
month; SMC group median, eight events per month), but 
significantly lower frequency for the CBT group at the end 
of the 12-session treatment (SMC group median, 6.75 events 
per month; CBT + SMC group median, two events per month) 
(P = 0.002), with a large between-group effect size (0.75). At 
the 6-month follow-up, the between-group effect size (SMC 
group median, five events per month; CBT + SMC group 
median, 1.5 events per month) was medium (0.42) and not 
statistically significant (P = 0.082). Therapist contact was 
greater in the active group, and this level of contact was not 
controlled for in the control group, which may explain the 
Table 2 Psychogenic nonepileptic seizures (PNES): how should 




The neurologist making the diagnosis and the 
mental health professional who will follow the 
patient are physically present when the diagnosis 
is revealed and discussed, and they both agree 
on the treatment plan
Objective discussion  
of findings
Description of the event as observed during 
video recording and the lack of ictal discharges, 
ruling out an epileptic etiology
Providers believe  
the diagnosis
Emphasis that the attacks are still considered 
real and out of the patient’s control
Explanation of the  
“psychogenic” nature  
of the attacks
An individualized hypothetical explanation is given 
on how these episodes may be taking place
Examples of trait vulnerabilities are highlighted
Patients may also be presented with examples of 
different forms of psychopathology (especially one 
they do not suffer from) to help them understand 
that other signs and symptoms in psychiatric 
disorders may be perceived as involuntary as well
The explanation may include discussion about 
the patient’s “brain” managing certain stressful 
situations in a particular manner
Psychotherapy  
referral
Psychotherapeutic interventions are introduced 
as an opportunity to learn new ways of relating 
to physical and emotional experiences, reducing 
vulnerability toward PNES, not as a promise to 
eradicate PNES for life




Emphasis is placed on the treatment of psychiatric 
comorbidities with both psychopharmacological 
and psychotherapeutic interventions
involvement of  
neurologist post  
diagnosis
Neurologists should remain involved and 
available and work collaboratively with mental 
health professionals to facilitate antiepileptic drug 
withdrawal, treatment of comorbid neurological 
conditions (including epilepsy), ongoing 
evaluation should new events or symptoms arise, 
and overall monitoring of the patient’s outcome
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Table 3 Treatment trials conducted in psychogenic nonepileptic seizures (PNES)
Reference Methods Results Comments
Trial design Intervention Final analysis (n) Dependent variables Data collection method
Goldstein et al60 Randomized, controlled CBT arm: 12 weekly or  
fortnightly hour-long sessions
SMC (both arms): supportive  
sessions with psychoeducation  
and AED withdrawal
64 Monthly event frequency, rate of  
event freedom, Work and Social 
Adjustment Scale, Hospital Anxiety  
and Depression Scale, modified  
Client Service Receipt inventory
Data collected at start of treatment, end  
of treatment, and at 6-month follow-up
Significantly lower event frequency at treatment  
end and a trend for lower event frequency  
at 6-month follow-up following CBT
Large between-group effect size at end of  
treatment and medium effect size at follow-up
No difference between groups in secondary  
measures
SMC group not controlled for therapist 
contact (which was greater in CBT)
Nature of treatment precludes blinding from 
SMC provider
Selection bias in favor of chronic, more 
difficult-to-treat patients
Willingness to enroll in study might have 
influenced favorable outcome in SMC group
6-month follow-up period too short for 
change in employment status
LaFrance et al61 Open-label, prospective,  
uncontrolled
12 weekly hour-long  
CBT sessions
20 Weekly event frequency, BDi,  
Modified HDRS, Davidson Trauma  
Scale, DES, BiS, Family Assessment  
Device, SCL-90, Oxford Handicapped   
Scale, Ways of Coping, QOLiE-31
Event frequency obtained for the week  
prior to enrollment, after enrollment,  
weekly during treatment, and at completion
Measures were obtained at baseline,  
during treatment, and after treatment
Mean event frequency decreased significantly  
from week 1 through end of treatment
Most scales assessing secondary outcome  
measures showed significant improvement from  
baseline to final session (except HDRS and DES)
Only individuals with v-EEG diagnosed PNES 
were included
Article states follow-up questionnaires were 
administered at months 4, 8, and 12 from the 
date of enrollment (although data not available)
Kuyk et al62 Open-label, prospective,  
uncontrolled
inpatient individualized  
CBT-based treatment for  
2–6 months (average,  
4.8 months)
22 Average weekly event frequency,  
SCL-90, BDi, State-Trait inventory,  
Utrecht Coping List, SF-36,  
Dissociation Questionnaire
Average weekly event frequency for  
previous 3 weeks at onset and end  
of treatment; average weekly event  
frequency for previous 4 weeks at  
6-month follow-up
Secondary measures also obtained  
at onset of treatment, discharge, and  
6-month follow-up
Significant decrease in event frequency from  
onset to discharge, from discharge to follow-up,  
and from onset to follow-up
27.3% achieved event freedom at end  
of treatment and 44% at follow-up
Significant decrease in BDI, State-Trait Inventory,  
dissociation questionnaire, and Utrecht Coping  
List from onset to discharge and in all measures  
from onset to follow-up
Diagnosis confirmed via EEG; comorbid 
epilepsy subjects excluded from analysis
inpatient setting not controlled for
Treatment was individualized, limiting 
generalizability of results
Sample selection bias toward patients with 
less severe psychiatric comorbidities, as this 
was an exclusion criterion for participation
Mayor et al64 Retrospective,  
naturalistic study,  
uncontrolled
Up to 20 sessions of brief  
augmented psychodynamic  
interpersonal therapy
47 Monthly event frequency,  
SF-36, PHQ-15
Questionnaire data collected 50 months  
(median) after baseline measures and  
42 months (median) after end of  
treatment
Psychosocial functioning measures  
obtained at baseline
At follow-up (median, 42 months after end of  
treatment), 25.5% of patients had become  
event free; a further 40.4% achieved an  
event reduction of .50%
Health care utilization declined significantly  
from baseline to follow-up, based on  
questionnaire
Some patients did not obtain PNES diagnosis 
with v-EEG
Contact with other providers and 
antidepressant treatment may have 
influenced outcomes
No predefined “time point” after therapy
Measurements of social functioning only 
obtained at baseline, not at follow-up
Barry et al66 Open-label, prospective,  
uncontrolled
32 weekly 90-minute group  
psychodynamic  
psychotherapy sessions
7 Weekly event frequency,  
BDi, SCL-90
Data collected at start of treatment,  
weekly for event frequency, and at  
16 and 32 weeks for secondary measures
Six of seven patients with decrease in event  
frequency over course of treatment
Four of seven with event cessation
Five subjects remained event free several  
months after treatment
Significant reduction in BDI over the course  
of treatment
Meaningful changes in ten of twelve SCL-90  
subscales
Five patients receiving individual 
psychotherapy concurrently, one with new 
antidepressant
Prigatano et al67 Open-label, prospective,  
uncontrolled
24 weekly 90-minute  
group psychoeducational  
interventions
9 Weekly event frequency, MMPi-2,  
and neurocognitive measures 
(WAiS-iii, CvLT, or RAvLT)
Weekly event log; weekly quiz  
about previous session
MMPi-2 and neurocognitive evaluation  
obtained during assessment period
Six patients reported a decrease in event  
frequency, two reported no change,  
and one reported an increase
Significant correlation between MMPI-2  
paranoid scale and frequency of events (positive)  
and correct answers in quiz (negative)
Typical conversion V profile observed
Two series of six and seven patients each; 
first series with no exclusion criteria; second 
series required pretreatment interview
One patient had comorbid epilepsy
Zaroff et al68 Open-label, prospective,  
uncontrolled
10 weekly hour-long  
group psychoeducational  
interventions
7 Pre- and posttreatment event  
frequency, Coping inventory  
for Stressful Situations, Davidson  
Trauma Scale, Curious Experiences  
Survey, STAXi-2, QOLiE-31
Pre- and posttreatment administration  
of all measures
Pretreatment questionnaire scores  
were compared with normative data  
(except event frequency) and with 
posttreatment score
No change in event frequency in four subjects  
(three had achieved remission at treatment  
initiation), a decrease in two subjects, and an  
increase in one subject
Significant reduction in Curious Experience Survey,  
Davidson Trauma Scale, and Coping inventory for  
Stressful Situations (Emotion Subscale), and STAXi-2 
Anger Expression index Score  
increase in QOLiE-31
All had v-EEG-confirmed diagnosis
Three of seven subjects had event freedom 
at treatment initiation
(Continued)
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Table 3 Treatment trials conducted in psychogenic nonepileptic seizures (PNES)
Reference Methods Results Comments
Trial design Intervention Final analysis (n) Dependent variables Data collection method
Goldstein et al60 Randomized, controlled CBT arm: 12 weekly or  
fortnightly hour-long sessions
SMC (both arms): supportive  
sessions with psychoeducation  
and AED withdrawal
64 Monthly event frequency, rate of  
event freedom, Work and Social 
Adjustment Scale, Hospital Anxiety  
and Depression Scale, modified  
Client Service Receipt inventory
Data collected at start of treatment, end  
of treatment, and at 6-month follow-up
Significantly lower event frequency at treatment  
end and a trend for lower event frequency  
at 6-month follow-up following CBT
Large between-group effect size at end of  
treatment and medium effect size at follow-up
No difference between groups in secondary  
measures
SMC group not controlled for therapist 
contact (which was greater in CBT)
Nature of treatment precludes blinding from 
SMC provider
Selection bias in favor of chronic, more 
difficult-to-treat patients
Willingness to enroll in study might have 
influenced favorable outcome in SMC group
6-month follow-up period too short for 
change in employment status
LaFrance et al61 Open-label, prospective,  
uncontrolled
12 weekly hour-long  
CBT sessions
20 Weekly event frequency, BDi,  
Modified HDRS, Davidson Trauma  
Scale, DES, BiS, Family Assessment  
Device, SCL-90, Oxford Handicapped   
Scale, Ways of Coping, QOLiE-31
Event frequency obtained for the week  
prior to enrollment, after enrollment,  
weekly during treatment, and at completion
Measures were obtained at baseline,  
during treatment, and after treatment
Mean event frequency decreased significantly  
from week 1 through end of treatment
Most scales assessing secondary outcome  
measures showed significant improvement from  
baseline to final session (except HDRS and DES)
Only individuals with v-EEG diagnosed PNES 
were included
Article states follow-up questionnaires were 
administered at months 4, 8, and 12 from the 
date of enrollment (although data not available)
Kuyk et al62 Open-label, prospective,  
uncontrolled
inpatient individualized  
CBT-based treatment for  
2–6 months (average,  
4.8 months)
22 Average weekly event frequency,  
SCL-90, BDi, State-Trait inventory,  
Utrecht Coping List, SF-36,  
Dissociation Questionnaire
Average weekly event frequency for  
previous 3 weeks at onset and end  
of treatment; average weekly event  
frequency for previous 4 weeks at  
6-month follow-up
Secondary measures also obtained  
at onset of treatment, discharge, and  
6-month follow-up
Significant decrease in event frequency from  
onset to discharge, from discharge to follow-up,  
and from onset to follow-up
27.3% achieved event freedom at end  
of treatment and 44% at follow-up
Significant decrease in BDI, State-Trait Inventory,  
dissociation questionnaire, and Utrecht Coping  
List from onset to discharge and in all measures  
from onset to follow-up
Diagnosis confirmed via EEG; comorbid 
epilepsy subjects excluded from analysis
inpatient setting not controlled for
Treatment was individualized, limiting 
generalizability of results
Sample selection bias toward patients with 
less severe psychiatric comorbidities, as this 
was an exclusion criterion for participation
Mayor et al64 Retrospective,  
naturalistic study,  
uncontrolled
Up to 20 sessions of brief  
augmented psychodynamic  
interpersonal therapy
47 Monthly event frequency,  
SF-36, PHQ-15
Questionnaire data collected 50 months  
(median) after baseline measures and  
42 months (median) after end of  
treatment
Psychosocial functioning measures  
obtained at baseline
At follow-up (median, 42 months after end of  
treatment), 25.5% of patients had become  
event free; a further 40.4% achieved an  
event reduction of .50%
Health care utilization declined significantly  
from baseline to follow-up, based on  
questionnaire
Some patients did not obtain PNES diagnosis 
with v-EEG
Contact with other providers and 
antidepressant treatment may have 
influenced outcomes
No predefined “time point” after therapy
Measurements of social functioning only 
obtained at baseline, not at follow-up
Barry et al66 Open-label, prospective,  
uncontrolled
32 weekly 90-minute group  
psychodynamic  
psychotherapy sessions
7 Weekly event frequency,  
BDi, SCL-90
Data collected at start of treatment,  
weekly for event frequency, and at  
16 and 32 weeks for secondary measures
Six of seven patients with decrease in event  
frequency over course of treatment
Four of seven with event cessation
Five subjects remained event free several  
months after treatment
Significant reduction in BDI over the course  
of treatment
Meaningful changes in ten of twelve SCL-90  
subscales
Five patients receiving individual 
psychotherapy concurrently, one with new 
antidepressant
Prigatano et al67 Open-label, prospective,  
uncontrolled
24 weekly 90-minute  
group psychoeducational  
interventions
9 Weekly event frequency, MMPi-2,  
and neurocognitive measures 
(WAiS-iii, CvLT, or RAvLT)
Weekly event log; weekly quiz  
about previous session
MMPi-2 and neurocognitive evaluation  
obtained during assessment period
Six patients reported a decrease in event  
frequency, two reported no change,  
and one reported an increase
Significant correlation between MMPI-2  
paranoid scale and frequency of events (positive)  
and correct answers in quiz (negative)
Typical conversion V profile observed
Two series of six and seven patients each; 
first series with no exclusion criteria; second 
series required pretreatment interview
One patient had comorbid epilepsy
Zaroff et al68 Open-label, prospective,  
uncontrolled
10 weekly hour-long  
group psychoeducational  
interventions
7 Pre- and posttreatment event  
frequency, Coping inventory  
for Stressful Situations, Davidson  
Trauma Scale, Curious Experiences  
Survey, STAXi-2, QOLiE-31
Pre- and posttreatment administration  
of all measures
Pretreatment questionnaire scores  
were compared with normative data  
(except event frequency) and with 
posttreatment score
No change in event frequency in four subjects  
(three had achieved remission at treatment  
initiation), a decrease in two subjects, and an  
increase in one subject
Significant reduction in Curious Experience Survey,  
Davidson Trauma Scale, and Coping inventory for  
Stressful Situations (Emotion Subscale), and STAXi-2 
Anger Expression index Score  
increase in QOLiE-31
All had v-EEG-confirmed diagnosis
Three of seven subjects had event freedom 
at treatment initiation
(Continued)
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Table 3 (Continued)
Reference Methods Results Comments
Trial design Intervention Final analysis (n) Dependent variables Data collection method
LaFrance et al69 Randomized,  
double-blind,  
placebo-controlled
Sertraline 25–200 mg daily  
versus placebo
33 Fortnightly event frequency, BDi,  
Modified HDRS, Davidson Trauma  
Scale, DES, BiS, Family Assessment  
Device, SCL-90, GAF, Oxford  
Handicapped Scale, Ways of  
Coping, QOLiE-31
initial visit: SCiD-i and pretreatment 2-week  
event frequency and baseline measures
Follow-up visit 2 weeks later with  
initiation of blinded treatment, biweekly  
visits for 12 weeks with measurement  
of event frequency
All measures and 2-week event  
frequency at week 12
No difference between treatment groups  
regarding event frequency by risk ratios
Relative change in biweekly event frequency from  
baseline to study end, separately, by treatment  
group with 45% decrease in the sertraline group  
versus 8% increase in the placebo group
No difference between groups in secondary  
measures
Not powered for establishing treatment 
efficacy because of limited sample size
Study not stratified to differentiate based  
on presence of personality disorders
Pintor et al70 Open-label, prospective,  
uncontrolled
All subjects with  
depressive and/or  
anxiety disorder
venlafaxine 75–300 mg daily  
by clinician criteria
19 Monthly event frequency, HDRS,  
HARS, Hospital Anxiety and  
Depression Scale
initial visit: SCiD-i and washout for  
15 days, if necessary
Follow-up visit 15 days later with initiation  
of venlafaxine treatment, monthly visits  
for 5 months with measurement with  
standardized scales (except SCiD-i)
Statistically significant reduction in all variables  
(including event frequency and depression and  
anxiety scales)
No difference in patients with more than  
ten events in 15 days
inclusion in study within 1–2 months of 
diagnosis (rather than a year) 
No direct efficacy outcomes on conversion 
symptoms in absence of affective or anxiety 
symptoms
No measurement of side effects
Abbreviations: AED, antiepileptic drug; BDi, Beck Depression inventory; BiS, Barrett impulsivity Scale; CBT, cognitive behavioral therapy; CvLT, California verbal 
Learning Test; DES, Dissociative Experiences Scale; EEG, electroencephalography; GAF, Global Assessment of Functioning; HARS, Hamilton Anxiety Rating Scale; HDRS, 
Hamilton Depression Rating Scale; MMPi-2, Minnesota Multiphasic Personality inventory 2; PHQ-15, Patient Health Questionnaire 15-item Somatic Symptom Severity 
Scale; QOLiE-31, Quality of Life in Epilepsy inventory 31; RAvLT, Rey Auditory verbal Learning Test; SCiD-i, Structured Clinical interview for DSM-iv Axis i Disorders; 
SCL-90, Symptoms Checklist-90; SF-36, 36-item Short Form Health Survey; SMC, standard medical care; STAXi-2, State-Trait Anger Expression inventory-2; v-EEG, video-
electroencephalography; WAiS-iii, Wechsler Adult intelligence Scale-iii.
decrease in between-group difference over time. At the same 
time, willingness to enroll in this study may have influenced 
the control group’s reduction in events.
LaFrance et al’s61 uncontrolled CBT study had 20 subjects 
enrolled and 17 completed a 12-week outpatient CBT protocol. 
The protocol was driven by similar principles as those of or 
Goldstein et al’s study,60 but it specifically followed a manual 
that focused on several points including mood-cognition-
environment connections; identification of moods, situations, 
and thoughts; relaxation techniques; healthy communication; 
and examination of internal and external triggers. Mean event 
frequency decreased significantly from week 1 (mean event 
frequency, 17.2 per week) through the end of treatment (mean 
event frequency, 7.1 per week) (P = 0.001). Eleven of the 17 
subjects completing the study (65%) reported no events per 
week during the final CBT session. Mean scores on measures 
of depression, anxiety, somatic symptoms, quality of life, and 
psychosocial functioning showed significant improvement 
from baseline to the end of treatment. The study does not con-
tain follow-up data beyond week 12, motivating future trials to 
examine if these strong results can be maintained over time.
An uncontrolled, prospective inpatient treatment program 
based on CBT principles has also provided evidence of reduc-
tion of seizure-like events.62 The treatment was provided over a 
prolonged inpatient admission, that allowed home visits during 
weekends, with a 4-week psychological diagnostic process, 
followed by a multidisciplinary treatment aimed at cognitive 
restructuring, trauma treatment, stimulus differentiation, cop-
ing skills training, stress management, behavioral analysis, 
and rational emotive therapy, all provided in individual and/or 
group settings. Family interventions were also included. The 
duration of the program ranged from 2 to 6 months, with an 
average duration of 4.8 months. The 22 completers showed a 
significant reduction between treatment initiation (mean event 
frequency, 6.6 per week) and end of treatment (mean event 
frequency, 3.0 per week) (P = 0.02) and 16 of them showed 
a significant reduction between treatment initiation and the 
6-month follow-up after discharge (mean event frequency, 0.9 
per week) (P = 0.002). Reductions between initiation of treat-
ment and the 6-month follow-up period were also observed in 
measures of depression, anxiety, dissociation, health-related 
quality of life, and overall psychopathology. Six months after 
discharge, 80% of 16 patients had an event reduction of over 
50% and half of these patients were event free. The prolonged 
inpatient setting where the treatment took place and the incor-
poration of several treatment strategies may have contributed to 
these positive results. At the same time, the multimodal nature 
of the treatment and the setting where it took place may repre-
sent limitations when it comes to adoption of this therapeutic 
approach for most PNES patients. Willingness to be admitted 
to an inpatient unit for over 2 months may represent a selection 
bias toward patients already open to the diagnosis.
Psychodynamic psychotherapies: augmented 
psychodynamic interpersonal therapy  
and group psychodynamic psychotherapy
According to psychodynamic theory, symptoms and behav-
iors are presumed to be influenced by internal   processes, 
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Table 3 (Continued)
Reference Methods Results Comments
Trial design Intervention Final analysis (n) Dependent variables Data collection method
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Coping, QOLiE-31
initial visit: SCiD-i and pretreatment 2-week  
event frequency and baseline measures
Follow-up visit 2 weeks later with  
initiation of blinded treatment, biweekly  
visits for 12 weeks with measurement  
of event frequency
All measures and 2-week event  
frequency at week 12
No difference between treatment groups  
regarding event frequency by risk ratios
Relative change in biweekly event frequency from  
baseline to study end, separately, by treatment  
group with 45% decrease in the sertraline group  
versus 8% increase in the placebo group
No difference between groups in secondary  
measures
Not powered for establishing treatment 
efficacy because of limited sample size
Study not stratified to differentiate based  
on presence of personality disorders
Pintor et al70 Open-label, prospective,  
uncontrolled
All subjects with  
depressive and/or  
anxiety disorder
venlafaxine 75–300 mg daily  
by clinician criteria
19 Monthly event frequency, HDRS,  
HARS, Hospital Anxiety and  
Depression Scale
initial visit: SCiD-i and washout for  
15 days, if necessary
Follow-up visit 15 days later with initiation  
of venlafaxine treatment, monthly visits  
for 5 months with measurement with  
standardized scales (except SCiD-i)
Statistically significant reduction in all variables  
(including event frequency and depression and  
anxiety scales)
No difference in patients with more than  
ten events in 15 days
inclusion in study within 1–2 months of 
diagnosis (rather than a year) 
No direct efficacy outcomes on conversion 
symptoms in absence of affective or anxiety 
symptoms
No measurement of side effects
Abbreviations: AED, antiepileptic drug; BDi, Beck Depression inventory; BiS, Barrett impulsivity Scale; CBT, cognitive behavioral therapy; CvLT, California verbal 
Learning Test; DES, Dissociative Experiences Scale; EEG, electroencephalography; GAF, Global Assessment of Functioning; HARS, Hamilton Anxiety Rating Scale; HDRS, 
Hamilton Depression Rating Scale; MMPi-2, Minnesota Multiphasic Personality inventory 2; PHQ-15, Patient Health Questionnaire 15-item Somatic Symptom Severity 
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SCL-90, Symptoms Checklist-90; SF-36, 36-item Short Form Health Survey; SMC, standard medical care; STAXi-2, State-Trait Anger Expression inventory-2; v-EEG, video-
electroencephalography; WAiS-iii, Wechsler Adult intelligence Scale-iii.
many times unconscious to the patient, with childhood 
experiences being highly influential to the development 
of persistent maladaptive behavioral patterns.14 Defense 
mechanisms such as dissociation and somatization are used 
to split traumatic memories from consciousness.63 The goal 
of psychodynamic therapy is to increase the patient’s aware-
ness of these patterns to facilitate change.14
Mayor et al64 studied brief augmented psychodynamic 
psychotherapy in 47 PNES subjects.64 Key features from 
this kind of psychotherapy include the assumption that the 
patient’s problems are linked to difficulties in his or her 
personal relationships, which are explained by interpersonal 
patterns developed earlier in life. The therapeutic mechanism 
of this approach is based on the identification and change of 
unhelpful interpersonal patterns and the more effective pro-
cessing of emotions related to both present and past issues. 
Techniques from somatic trauma therapy, such as control of 
autonomic arousal, tracking of somatic symptoms, linkage 
to emotional triggers, and processing of traumatic memories, 
are used to “augment” the psychodynamic interpersonal 
approach.65 The 47 subjects completed up to 20 weekly or 
fortnightly sessions (range, one to eighteen sessions; median, 
five sessions); twelve of these subjects (26%) achieved event 
freedom 42 months (median) after the conclusion of therapy 
and a further 19 subjects (40%) reported more than 50% 
reduction in event frequency compared with   baseline. The 
median frequency of events per month decreased from six 
at baseline to one at follow-up (P , 0.007). There was also 
a significant decline in health care utilization at follow-up. 
Some of these patients had not obtained the diagnosis of 
PNES through v-EEG confirmation, relying on clinical 
impression by a neurologist with expertise in epilepsy, direct 
observation of the events in clinic, video recordings, or a 
history or witness account suggestive of PNES. Contact 
with other providers, such as a neurologist, or prescription of 
antidepressant or anxiolytic medication may have influenced 
improvement as well.
A few studies have evaluated group psychotherapy in 
the treatment of PNES. Barry et al66 reported on the effi-
cacy of a 32-week-long psychodynamically oriented group 
psychotherapy, which had as a goal the conscious and 
verbal expression of emotional distress, obviating the need 
for somatic displays of stress. Development of assertive 
coping strategies instead of passive avoidant behavior was 
emphasized. Six of the seven (86%) completers experienced 
a decrease in frequency of events over the treatment period. 
Four of the seven (57%) achieved complete remission, with 
very occasional recurrence in the face of emotional distress. 
Depression severity and overall severity of psychopathology 
also showed improvement.
Other group interventions
Prigatano et al67 reported a decrease in six of nine subjects 
(67%) with PNES during completion of a 6-month group 
psychotherapy program. The treatment consisted of 24 
90-minute sessions that reviewed facts about epilepsy and 
PNES and where discussion of feelings that may relate to 
past or present events relevant to PNES was encouraged. 
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Results were based on a comparison between number of 
events during the first twelve sessions and number of events 
during the second twelve sessions.
Zaroff et al68 reported on the efficacy of a 1-hour weekly 
group psychotherapy intervention over the course of 10 weeks. 
The approach was psychoeducational in nature and it covered 
topics including PNES, anger, trauma and abuse, somatization 
tendencies, quality of life, and stress management techniques, 
among others. Four of the  seven completers (57%) who were 
enrolled in this program experienced no change in event fre-
quency, but in three of these four subjects (75%), event ces-
sation had been achieved at treatment initiation. Two subjects 
experienced a decrease and one an increase in event frequency. 
Decreases were seen in post-traumatic and dissociative 
symptoms and emotionally based coping mechanisms. The 
report does not mention if patients also received additional 




The lack of a consistent neurobiological model in PNES 
makes identification of a customized neurochemical inter-
vention unrealistic at this stage. However, under the premise 
that difficulties with impulsivity, compulsive tendencies, 
depression, and anxiety are associated with serotonergic 
deficits and these conditions are usually seen comorbidly 
in PNES,14 serotonin reuptake inhibitors, both selective 
and dual action, have been investigated as potentially use-
ful compounds.
LaFrance et al69 conducted a randomized, double-blind, 
placebo-controlled trial evaluating the efficacy of flexible-
dose sertraline over 12 weeks at reducing PNES frequency 
and improving other psychiatric severity and psychosocial 
measures. The final analysis included 33 subjects with one 
or more events in the 2 weeks prior to enrollment. Patients 
were allowed to participate if taking other antidepressants, 
except for monoamine oxidase inhibitors and sertraline at a 
100 mg/day or higher dose for more than 30 days. Dose of the 
concurrent antidepressants, if prescribed, was held   constant. 
There was no difference between groups in fortnightly event 
frequency change (risk ratio, 0.51; P = 0.29). However, when 
groups were analyzed separately, the sertraline arm showed a 
45% decrease in biweekly event frequency (P = 0.03), while 
the control group showed an 8% increase (P = 0.78). There 
were no between-arm   differences in secondary outcome 
measure changes. The limited sample size means this well-
conducted study is not powered enough to establish treatment 
efficacy. The sertraline group had a higher rate of baseline 
event frequency in those subjects with Axis II disorders than 
in those without Axis II disorders; this baseline difference 
was not observed in the control group. The study was not 
stratified to differentiate results based on the presence of 
personality disorders.
An open-label, prospective, uncontrolled study of 
flexible-dose venlafaxine evaluated event reduction as well 
as anxiety and depression severity.70 All enrolled subjects 
had v-EEG-confirmed PNES but also had to meet criteria 
for a unipolar depressive disorder and/or anxiety disorder. 
Subjects underwent monthly assessments for 5 months. The 
19 subjects who completed the study showed a statistically 
significant reduction in all symptom scales and monthly 
event frequency at the fifth-month assessment compared 
with the initial assessment. There was no difference in 
patients with more than ten events in the 15-day baseline 
pre-inclusion assessment period. That the inclusion of 
PNES subjects after diagnosis was confirmed no earlier 
than 2 months from enrollment may have assisted in the 
attention provided to the diagnosis; however, this may be 
irrelevant, as the mean duration of PNES was 6 years in 
this study.
Discussion and future directions
One pilot psychopharmacotherapeutic study meeting criteria 
for Class II evidence69 and one pilot psychotherapeutic study 
meeting criteria for Class III evidence60 are the scientifically 
strongest evidence currently available for the treatment of 
PNES.71 Both studies had limited power, and while strong 
support cannot be claimed for these interventions at this 
point, it is appropriate to say that these are very promising 
approaches that require further study. This limited evidence 
shows how early the current stage is in the development of 
therapeutic interventions for this clinical entity. The lack of 
a clear-cut etiological model that supports the psychogenic 
origin of PNES, and the heterogeneous background that can 
lead to a similar phenotypic presentation, can make find-
ing an explanation for the disorder and a one-size-fits-all 
intervention a difficult task to achieve. On the other hand, 
the field of psychiatry is known to accommodate etiologi-
cal uncertainties and a wide variety of risk factors that can 
lead to a specific symptom display while still investing 
in the development of treatment interventions. Why are 
PNES lagging behind then in treatment development? Is 
the fact that many of these patients are initially thought to 
have epilepsy a reason for this cold embrace and, to some 
degree, skepticism?
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Because most PNES patients enter diagnosis and 
treatment through the “epilepsy” door, the collaboration 
between neurology and psychiatry is of utmost relevance. 
Dual training or neuropsychiatric specialization may help 
bridge this dichotomy, although there may be a limited 
number of professionals with such background and inter-
est. “Treatment as usual” for PNES mostly depends on a 
referral to a mental health professional.10 For individuals 
who accept the diagnosis without hesitation, who do not 
possess chronic risk factors that perpetuate their symp-
toms, and who are able to find a competent professional 
comfortable treating PNES, “treatment as usual” may 
prove therapeutic. However, for many patients, limited 
acceptance of the diagnosis, a number of chronic psychi-
atric difficulties, and limited therapeutic resources still 
represent barriers to adequate treatment that can lead to a 
successful outcome.
A multidisciplinary and flexible model for the treatment 
of PNES may provide the background infrastructure neces-
sary upon which the specific psychiatric interventions may 
be deployed successfully. Beyond the development of this 
infrastructure, understanding the vulnerabilities that lead to 
PNES may help customize many of the interventions with 
the goal of providing long-term beneficial outcomes. While 
the understanding of these vulnerability traits is still at an 
early stage,8 these traits may be key ingredients that need to 
be recognized and addressed for a durable, positive outcome 
in therapeutic trials and actual practice. Additionally, the role 
of the therapeutic relationship cannot be underestimated, as 
it may provide the basis for further adaptive development of 
emotional expression and identity.72
Although a case series and therefore not included in the 
author’s earlier analysis, Rusch et al11 reported on 26 PNES 
adults who received diverse psychotherapeutic interventions 
of varying duration based on the symptom pattern underlying 
their PNES presentation. All subjects except one experienced 
either cessation or improvement of their events. Treatment 
was not delivered in a standardized fashion. This article is 
mentioned because, although not a standardized interven-
tion, it does capture the essence of the heterogeneous patient 
population that PNES patients are, and it demonstrates how, 
even with individualized treatment, follow-up data can be 
prospectively tracked.
Evaluation of structured therapies such as CBT, psycho-
dynamic therapies and group interventions, and serotoner-
gic antidepressants in larger, randomized, controlled trials 
are necessary to establish solid guidelines for treatment. 
Event induction through hypnosis has been evaluated to 
help discriminate between epileptic seizures and PNES,73,74 
creating interest in hypnotherapy as a potentially effective 
intervention. Hypnotherapy was studied in conversion, but 
not in PNES-only samples in a rigorous manner, limiting 
comparison with the interventions mentioned earlier.22,23 
Additionally, other psychotherapeutic approaches such as 
mindfulness-based interventions, EMDR, and sensorimotor 
therapy have not been systematically studied and may be 
well suited for PNES.
Mindfulness-based interventions are rooted in the con-
cept of mindfulness, “paying attention in a particular way: 
on purpose, in the present moment and non-judgmentally.”75 
Mindfulness has been articulated in specific psychothera-
peutic approaches, such as acceptance and commitment 
therapy,76 dialectical behavioral therapy,77 mindfulness-based 
stress reduction,75 and mindfulness-based cognitive therapy.78 
The application of mindfulness practice can lead to a shift 
in perspective, termed “reperceiving,” which becomes an 
overarching mechanism of action under which more direct 
mechanisms, can lead to change and positive outcomes.79 
The emphasis of mindfulness-based interventions on inten-
tional and nonjudgmental attention in the present moment, 
followed by an acceptance stance and behavioral choice 
based on high-value roles, could help conversion and dis-
sociation patients develop new strategies to eventually 
replace their maladaptive ones dictated by their vulner-
ability traits.80
Sensorimotor therapy has been specifically developed 
for the treatment of trauma and dissociation. The goal of 
sensorimotor therapy is to help the individual process his or 
her traumatic experience within a state of “optimal arousal,” 
instead of the usually displayed hypearoused (ie, reexperi-
encing, hypervigilance) or hypoaroused (ie, dissociation, 
freezing response) states.81 Given the high prevalence of 
traumatic experiences and also the identified hypervigilance82 
and avoidance tendencies in PNES subjects,83 this kind of 
treatment may hold some promise for at least a subset of 
patients.
EMDR has shown results comparable with those of CBT 
in the treatment of PTSD, and its proposed mechanism of 
action involves processing of trauma memories with new, 
positive information, separating the arousal associated with 
these memories. This is achieved by creating a vivid image 
of the traumatic memory while the patient is led through eye 
movements and other tactile stimulations.36 The creation of 
a new mechanism to process these memories without the 
associated arousal may also be fitting to PNES patients, 
especially considering the high prevalence of PTSD in this 
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population. Although no rigorous studies were conducted in 
PNES, a case series of three subjects with PNES and PTSD 
rendered event remission, with this event remission being 
sustained for 12–18 months.84
Similarly, as more is learned about the underlying 
  neurocircuitry dysfunction in PNES,85 effective treatments 
may be strengthened by neuromodulatory interventions.
Conclusion
This review presented the current state in the treatment of 
PNES, including limitations and difficulties in conducting 
clinical trials in this population and a proposed model for 
diagnosis presentation. A review of the most recent medical 
literature was provided with a detailed description of those 
studies with the scientifically strongest evidence of efficacy. 
Finally, concerns regarding the delay in PNES treatment 
development and some practical ideas on how to create 
an infrastructure for successful treatment outcomes were 
discussed.
CBT and the antidepressant sertraline were evaluated 
in pilot double-blind, randomized, controlled trials. Other 
interventions evaluated in uncontrolled trials include aug-
mented psychodynamic interpersonal psychotherapy, group 
psychodynamic psychotherapy, group psychoeducation and 
the antidepressant venlafaxine. These ineterventions all 
seem promising, but require further investigation in larger 
samples and/or with a more rigorous methodology. Suc-
cessful outcomes in clinical practice will be dependent on 
adaptation and flexible delivery of these interventions. 
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